欢迎访问《现代生物医学进展》编辑部！

Home

About Journal

Editorial Board

Editor

Guide

Academic

Certificate

中文

Article Summary

李月月张立婷张璨朱克祥李俊峰陈青锋.DC-CIK治疗对晚期肝细胞癌患者免疫功能及循环肿瘤细胞的影响[J].现代生物医学进展英文版,2017,17(6):1066-1069.

DC-CIK治疗对晚期肝细胞癌患者免疫功能及循环肿瘤细胞的影响

The Effects of DC-CIK Therapy on Immune Function and Circulating TumorCells in Patients with Advanced Hepatocellular Carcinoma

DOI：

中文关键词: DC-CIK细胞治疗肝细胞癌甲胎蛋白循环肿瘤细胞 T细胞亚群

英文关键词: DC-CIK cell therapy Hepatocellular carcinoma AFP Circulating tumor cells T cell subsets

基金项目:甘肃省科技重大项目（1302FKDA029）；甘肃省自然科学基金项目（1506RJZA263）

Author Name	Affiliation
李月月张立婷张璨朱克祥李俊峰陈青锋	兰州大学第一临床医学院；兰州大学第一医院传染科；兰州大学第一医院普外科；兰州大学第一医院检验科

Hits: 1034

Download times: 0

中文摘要:

目的：研究DC-CIK 细胞治疗对晚期肝细胞癌患者甲胎蛋白、免疫功能及循环肿瘤细胞数的影响。方法：选取2013 年至2015 年我院收治的26例肝细胞癌并伴有复发或转移的患者，对其治疗前后甲胎蛋白、免疫功能及循环肿瘤细胞数的数据进行分析，比较DC-CIK 细胞治疗前后甲胎蛋白、循环肿瘤细胞、免疫功能的变化。根据细胞治疗次数分为1 次组及>1 次组，比较两组免疫功能的变化。结果：DC-CIK 细胞治疗前甲胎蛋白为(603.32± 155.78) ng/mL，细胞回输后为(571.24± 147.49) ng/mL，差异无统计学意义(P＞0.05)。DC-CIK 细胞治疗前及细胞回输后CTC检测阳性率分别为81.8 %、36.4 %；治疗前及回输后循环肿瘤细胞数量分别为(8.36± 10.642)、(1.55± 2.464)，细胞治疗前后比较差异均有统计学意义(P<0.05)。细胞治疗前1 天T 细胞亚群CD3+、 CD3+CD4+、CD3+CD8+、CD4/CD8 分别为(66.05± 15.31)%、(41.89± 12.33)%、(23.15± 8.05)%、(2.10± 0.77)，回输后分别为(69.69± 12.91)%、(44.80± 11.11)%、(23.13± 7.12)%、(2.29± 0.91)，治疗前后比较差异无统计学意义(P>0.05)。细胞治疗次数1 次组和>1 次组免疫功能变化差异无统计学意义(P>0.05)。结论：DC-CIK 细胞治疗可减少肝细胞癌伴复发或转移患者循环肿瘤细胞的数量，但对甲胎蛋白和免疫功能无明显影响。

英文摘要:

Objective:To investigate the effects of DC-CIK cell therapy on AFP, immune function and number of circulating tumor cell in patients with advanced hepatocellular carcinoma.Methods:26 cases of hepatocellular carcinoma with recurrence or metastasis were selected from 2013 to 2015, the data of AFP, immune function and number of circulating tumor cell were analyzed before and after DC-CIK treatment, the changes of AFP, immune function and number of circulating tumor cell were compared. Based on frequency of cell therapy, the patients were divided into 1 time group and more than 1 time group, the changes of immune function were compared between two groups.Results:AFP was (603.32± 155.78) ng/mL one day before DC-CIK cell therapy and (571.24± 147.49) ng/mL after reinfusion (P>0.05). One day before DC-CIK cell therapy and after cell transfusion, the positive rate of CTC were 81.8 %, 36.4 % respectively; number of circulating tumor cells were (8.36 ± 10.642), (1.55 ± 2.464) one day before treatment and after the reinfusion respectively (P<0.05). The CD3+, CD3+ CD4+, CD3+ CD8+, CD4/CD8 were (66.05± 15.31) %, (41.89± 12.33) %, (23.15± 8.05) %, (2.10± 0.77) one day before treatment and (69.69± 12.91) %, (44.80± 11.11) %, (23.13± 7.12) %, (2.29± 0.91 ) after infusion respectively (P>0.05). The immune function showed no statistic significance between 1 time group and more than 1 time group (P>0.05).Conclusion:DC-CIK cell therapy could reduce number of circulating tumor cells in patients suffering from hepatocellular carcinoma with recurrence or metastasis, but had no significant effect on the serumAFP level and immune function.

View Full Text View/Add Comment Download reader